NASDAQ · ASND
Ascendis Pharma A/S
$253.00+$3.45 (+1.38%)
Ascendis Pharma A/S’s quoted price sits in the upper half of its reported 52-week range, 10.33% below the high.
Loading market information…
NASDAQ · XERS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Xeris Biopharma Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Xeris Biopharma Holdings, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Xeris Biopharma Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.06+14.29% vs estimate | $60.12M+4.36% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | -$0.03+62.5% vs estimate | $60.10M+9.47% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -$0.06+33.33% vs estimate | $52.86M+2.75% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $15.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$253.00+$3.45 (+1.38%)
Ascendis Pharma A/S’s quoted price sits in the upper half of its reported 52-week range, 10.33% below the high.
$85.95-$0.33 (-0.38%)
Corcept Therapeutics Incorporated’s quoted price sits in the upper half of its reported 52-week range, 31.99% below the high.
$54.54+$0.38 (+0.7%)
MBX Biosciences, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 24.92% below the high.
$45.23+$0.98 (+2.21%)
Septerna Inc’s quoted price sits in the upper half of its reported 52-week range, 11.49% below the high.
$53.67+$1.87 (+3.61%)
Eton Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.14% below the high.
$21.50+$0.79 (+3.81%)
GH Research PLC’s quoted price sits in the lower half of its reported 52-week range, 31.62% below the high.
$3.50+$0.07 (+2.04%)
MannKind Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.24% below the high.
$46.82-$0.17 (-0.36%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.71% below the high.
